Kevin S. Boyle, Sr

2022

In 2022, Kevin S. Boyle, Sr earned a total compensation of $1.8M as Chief Executive Officer at ZIOPHARM Oncology, a 61% decrease compared to previous year.

Compensation breakdown

Bonus$270,000
Option Awards$904,000
Salary$600,000
Other$18,818
Total$1,792,818

Boyle received $904K in option awards, accounting for 50% of the total pay in 2022.

Boyle also received $270K in bonus, $600K in salary and $18.8K in other compensation.

Rankings

In 2022, Kevin S. Boyle, Sr's compensation ranked 1,933rd out of 5,672 executives tracked by ExecPay. In other words, Boyle earned more than 65.9% of executives.

ClassificationRankingPercentile
All
1,933
out of 5,672
66th
Division
Manufacturing
1,025
out of 3,081
67th
Major group
Chemicals And Allied Products
434
out of 1,396
69th
Industry group
Drugs
397
out of 1,297
69th
Industry
Pharmaceutical Preparations
284
out of 940
70th
Source: SEC filing on April 25, 2023.

Boyle's colleagues

We found two more compensation records of executives who worked with Kevin S. Boyle, Sr at ZIOPHARM Oncology in 2022.

2022

Drew Deniger

ZIOPHARM Oncology

VP, Research and Development

2022

Melinda Lackey

ZIOPHARM Oncology

SVP, Legal & Administration

News

In-depth

You may also like